TW588018B - Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof - Google Patents
Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof Download PDFInfo
- Publication number
- TW588018B TW588018B TW092121052A TW92121052A TW588018B TW 588018 B TW588018 B TW 588018B TW 092121052 A TW092121052 A TW 092121052A TW 92121052 A TW92121052 A TW 92121052A TW 588018 B TW588018 B TW 588018B
- Authority
- TW
- Taiwan
- Prior art keywords
- water
- soluble
- dispersible
- item
- scope
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 15
- 229940031182 nanoparticles iron oxide Drugs 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 239000002105 nanoparticle Substances 0.000 claims abstract description 62
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 claims abstract description 7
- 239000002245 particle Substances 0.000 claims description 26
- 150000007524 organic acids Chemical class 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- 235000013339 cereals Nutrition 0.000 claims 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 150000007523 nucleic acids Chemical class 0.000 abstract description 2
- 102000039446 nucleic acids Human genes 0.000 abstract description 2
- 108020004707 nucleic acids Proteins 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- 238000000975 co-precipitation Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 14
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 10
- 239000002872 contrast media Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 241000399119 Spio Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 229920001100 Polydextrose Polymers 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000002122 magnetic nanoparticle Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000013856 polydextrose Nutrition 0.000 description 3
- 239000001259 polydextrose Substances 0.000 description 3
- 229940035035 polydextrose Drugs 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241001673391 Entandrophragma candollei Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- -1 propyl- Chemical group 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
- C01G49/02—Oxides; Hydroxides
- C01G49/08—Ferroso-ferric oxide [Fe3O4]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1836—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/04—Particle morphology depicted by an image obtained by TEM, STEM, STM or AFM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Radiology & Medical Imaging (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Composite Materials (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
玖、發明說明: 【發明所屬之技術領域】 本發明係有關一種水溶性及分散性之氧化鐵(Fe⑹奈 米粒子之製造方法及其作為磁共振造影㈣劑及磁能導引 之相關分子生物技術及臨床檢測、診斷、治療之應用應用。 【先前技術】 j 奈米粒子(nanoparticles) 一般而言係指粒徑範圍從 lnm至l〇〇nm之間之微細粒子,由於奈米粒子微小之尺寸, =面效應與體積效應使得奈米粒子本身具有許多特殊之性 質,例如··極高的表面積與表面能量、不連續的電子能階、 特殊光的吸收、單磁區的產生…等特性,因此,奈米粒子在 新材料之開發上具有極大的潛力。每個帶磁性之奈米粒子都 有一定的磁場定向,但是當粒子變得很小時,其磁場會變得 很不穩定,美國喬治亞理工學院的科學成功發現,精確控制 ,性奈米粒子之大小及磁性,則可利用此磁性奈米粒子攜帶 藥品注射入病人體内,再利用磁力將藥品輸送至身體各部 ^,藉此協助醫生準確地治療疾病,此外,磁性奈米粒子亦 可改善目4的磁共振掃描(magnetic resonance imaging) 技術增加影像之對比度以幫助醫生檢查腫瘤細胞、動脈硬 化斑、中樞神經系統等疾病。 大多數氧化鐵奈米粒子在生物醫學使用上都會包覆一 層f質增加水溶性與分散性,這些覆蓋物質為蛋白素、親水 性问分子、殿粉和聚合葡萄糖。在靜脈注射方面,包覆了親 生物貝後的氧化鐵奈米粒子整個大小約為30到150nm都 有,而且以聚集型為主。 目m已知製造Fe3〇4的技術是在有機相中產生均勻分佈 588018 奈米粒子,而在水溶液相中則多以聚集型為主。雖然可以藉 由加入高分子或界面活性劑在粒子表面形成保護層而在水 /合液中得到分散的奈米粒子,但通常粒子表面受到高分子 或界面活性劑分子保護不易與生物分子結合作進一步的應 用另外連、,,σ後之複合結構穩定性不佳易產生沉殿等現象, 進而影響其應用性。然而,絕大部分之生物分子皆為水溶性 物質,倘若要將奈米粒子制於生醫領域巾,製備具水溶性 且均勻分散性之奈米粒子之技術將是非常重要之環節。 此外,目前市售之顯影劑係以含有Gd3+為主,為一種重 金屬,對細胞具有毒性,不當的劑量使用或劑型設計容易影 響人體健康,且使用W顯影劑有時會出現「偽訊號」的現 象,或是因體内分泌影響而稀釋其濃度造成訊號消失等缺 點。因此’藉由氧化鐵奈米粒子的特殊超順磁特性製成更適 於人體醫療診斷之顯影劑,較之有更高之安全性為一值得開 發之技術。 發明内容】
有鑑於習知製造水溶性及分散性之氧化鐵奈米粒子 各種弊端及以及料磁共振顯影劑之_,本發明 僅能在水相製程中產生具高度水溶性特質的氧化鐵,並且 超順磁性之磁導能力及作為磁共振顯景“ Resonance Imaging,MRI)的顯影劑,且由於i單純之罗 介面及水相中之製程易於生物分子及藥劑聯結,而能進: 發展為功能性造影及標的型治療策略的平△技賞 本發明之目的之-係提供—種水溶性;分:性之以 奈未粒子之製造方法’包含下列步驟:(a)將含有…及卜 6 之溶液以特定濃度比例混合;(b)加入適量之有機酸作為附 著劑,(c)將溶液pH值控制至1〇以上使沉殿物產生;(d) 收集並清洗該沉澱物;(e)再加入過量之有機酸作為附著 劑,(f)加入適當有機溶劑及水以去除前述過量之有機酸; 及(g)收集純化後之Fe3〇4奈米粒子。 其中前述步驟(a)之Fe2+及Fe3+溶液之特定濃度混合比 例並無一定限制,較佳為1:2〜1··4,最佳係為1:2。 知其中前述步驟(b)及(e)之有機酸係可選自下列群組··醋 酸、半胱胺酸(cysteine )、丙胺酸(Alanine)、甘胺酸 (glycine)及油酸,其中係以甘胺酸效果最佳。步驟及(㊀) 1可使用相同或不相同有機酸,較佳係為使用相同之有機 酸。該有機酸係作為附著劑,步驟⑻係先利 ^反應物共存之技術製得㈣4奈米粒子,步驟⑷再力= 達到奈米粒子表面覆蓋完全之目的,順 陡及刀政性之FesO4奈米粒子。 -中則ι4步驟(c)係可藉由加入驗性物質調整邱值,例 如· NaOH、NHWH或其他類似物。 ::引述步驟⑴之有機溶劑係可選自下列群組:丙 -。、甲醇、乙醇及正己烷,其中較係為丙綱。 饥其t前述製造方法較佳料2()〜机下進行,最佳係為 本&月之$目的係提供_種f⑽氧 ^ 其特徵為:具有水溶性 孰不木拉子 2 2⑽。 /讀及刀政性,且粒子大小為6.2nm ± 本發明之另一目的在姐 係包含由前述製造方法^之";種磁共振造影顯影劑,主要 万去衣成之水溶性及分散性之Fe3〇4奈米 粒子及水。 本發明之方法係可克服現有技術之缺點,製造出分佈均 句、可溶於水但並未添加任何高分子及界面活性劑之Fe办 奈米粒子’並可應用於作為磁共振造影之顯影劑,未來將可 廣泛地應用於生醫檢測及醫療部分。 【實施方式】 本發明之具有高度水溶性及分散性之Fe3Q4奈米粒子之 製2造方法3流程圖,如第一圖所示,包含下列步驟:將含有
Fe2及Fe3+之溶液以特定濃度比例混合;加入適量之有機酸 作為附著劑;調整溶液pH值至大於1〇之鹼性環境以產生
Fe^奈米粒子沉澱物;收集並清洗該以也奈米粒子沉澱 物;再加入過量之有機酸作為附著劑;加入適當有機溶劑及 水以去除前述過量之有機酸;及收集純化後之以也奈米粒 子。 以下仏長:供貫施例加以說明本發明之水溶性及分散性 Fe^奈米粒子之製造方法及其做為磁共振造影顯影劑之應 用,俾使更清楚本發明之優點。 實施例1 :水溶性Fe3〇4之奈米粒子之製造 首先,將0· 2M之FeCl2及〇· 1M之FeCl3分別溶於2M 之HC1水溶液,以體積比1:4 (FeCl2 : FeCl3)之比例混合, 之後加入1克之甘胺酸(較佳為〇 · 5〜1 · 5克)作為附著劑, 接著慢慢滴入5M NaOH水溶液調整混合液中的pH值大於1〇 以提供一鹼性環境使溶液中Fe3〇4沉澱出來,之後再授拌1〇 分鐘後用二次水清洗數次,收集該黑色沉殿物(p>e3Q4);接 著,加入3克甘胺酸作為附著劑,攪拌10〜15分鐘後再震盪 鐘以使附著劑可完全覆蓋Fe3〇4奈米粒子表面,之後將 所知之Fe3〇4奈米粒子加入丙酮與水的混合液中以去除過量 ^有機酸附著劑,再以8000rmp之轉速離心2〇分鐘使以也 $米粒子沉澱,即可獲得本發明之水溶性及分散性之以必 示米粒子。第一圖係頰示將本實施例之以心奈米粒子溶於 —人水中之電子顯微影像圖,其粒子大小為± 2 2 nm ’由圖中顯示本發明之奈米粒子確實具有高度水溶 性及分散性之特點,且可穩定的長時間存在於水溶液中。 貫施例2:以pe3()4奈米粒子作為磁共振造影之顯影劑—注 射於肝臟 本實施例係使用前述實施例i製成之奈米粒子作 為磁共振造影之顯影劑,其製法僅需將以心奈米粒子溶於 一次水中,亚可視需要適量添加血清等類似體液之添加物即 可製得顯影劑。 第三(A)圖係顯示肝臟中未注射以心奈米粒子顯影劑前 之磁共振造影圖;第三⑻圖係顯示肝臟中注射G 86^的 FeW奈米粒子顯影劑後之磁共振造影圖,比較第三及第 三⑻圖中箭頭所指處可清楚看出,奈米粒子顯影劑得 確可進入肝臟中達到顯影效果。 貫施例3·以pe3G4奈米粒子料磁共振造影之顯影劑—注 射於腎臟 同前述實施例2所使用之_4奈米粒子之磁共振造影 顯影劑’I實施例係將之注射於腎臟中觀察其顯影之效果。 第四(A)圖係顯示腎臟中未注射^奈米粒子顯影劑 588018 前之磁共振造影圖·,第四(B)圖係顯示肝臟中注射〇86gM 的FeA奈米粒子顯影劑後之磁共振造影圖,比較第四 及第四⑻圖中前頭所指處可清楚看出,奈米粒子顯影 劑得確可進入腎臟中達到顯影效果。 實施例4:以^〇4奈米粒子作為磁共振造影之顯影劑 之安全性測試 以大鼠為測試對象’將以分別注射5mg/Kg量的^必 奈米粒子後,分別於〇、2、4、6週後計算其存活率,結果 如第五圖所示’經注射Fe304奈米粒子之大氣皆無死亡,存 活率為1嶋,因此以Fe3〇4奈米粒子作為顯影劑係符合安全 之考量。 •综上所述’本發明之技術相較於習知技術具有以下優 黑占· 1. ^發明之技術不需藉由親水性高分子、界面活性劑 分子、蛋白素、澱粉和聚合葡萄糖等保護下即可妒 備出高水溶性、分散均勻之F e3 04奈米粒子,對於後 續之表面修飾與連結提供更大之設計空間。 2. 本?明之Fe3〇4奈米粒子可與核酸及蛋白質等生物分 子藉由共價鍵或非共價鍵形成各種結合方式,以應 用於生化醫療方面。 "" 3. 使用本發明之Fe3〇n好製成之磁隸造影顯影 劑相較於目前市售顯影劑材料,本發明之Fe3〇4夺米 粒子的大小非常小(6.2nm ±2.2nm),並且由於太 米化而呈現之超順磁特性,其中弛緩速率n值遠低 於市售SIP 0顯影劑系統(亦為氧化鐵奈米粒子之顯 影劑)’表-是將本發明之Fe304奈米粒子,市售SIP0 10 588018 與含Gd3+之顯影劑的弛緩速率T1與T2比較。 表一 本發明之 Fe3〇4 奈 米粒子顯 影劑 市售SIPO 顯影劑 市售Gd3+ 之顯影劑 T1 34ms 176ms 74.4ms T2 23ms 0.77ms *以上皆以相同濃度4.61 mM(金屬離子濃度)之顯影劑情況 下做比較。 1. 表一所測得的T1值,本發明之Fe304奈米粒子比
SPIO與含Gd3+之顯影劑要低,但在T1顯影效果比 較,Gd3+是優於氧化鐵(在離子濃度為1E-1〜1E-2 M),不過本發明之Fe304奈米粒子則優於SPIO,無 論是以血清(serum)或是水當作溶劑的條件下。 2. 表一所測得的T2值,本發明之Fe304奈米粒子並未 比SPIO低,但在T2的顯影效果比較,本發明之Fe304 奈米粒子在離子濃度為1E-1〜IE-2 Μ條件時與 SPIO的比較並無差別。 3. 本發明之Fe304奈米粒子顯影劑相較於市售SIP0顯
影劑系統(亦為氧化鐵奈米粒子之顯影劑)並無澱 粉和聚合葡萄糖等保護之下就能溶於水溶液並呈分 散型態,同時T1顯影效果比市售SIP0顯影劑好且 T2顯影也與市售SIP0顯影劑無太大差異。 4. 本發明之Fe304奈米粒子顯影劑相較於市售Gd3+之 顯影無高毒性問題、低免疫刺激性且不會在生物體 内產生沉殿。此外,相較於稀土族的Gd3+製程價格 更低並且不需要螯合劑保護。 雖然本發明之較佳實施例以揭露於上,然其並非用以限 11 588018 定本發明,任何熟習此項技藝者,在不脫離本發明之精神和 範圍内,皆可作各種變化,因此本發明之保護範圍係由後述 之申請專利範圍所界定。
12 588018 【圖式之簡單說明】 第〆圖係顯示本發明之Fe3〇4奈米粒子之製造方法流程 圖。 第二圖係顯示本發明製得之Fe3〇4奈米粒子溶於水中之 電子顯微鏡照片。 第三(A)圖係顯示未注射FhO4奈米粒子顯影劑前之肝臟 磁共振造影圖。 第三(B)圖係顯示已注射FesO4奈米粒子顯影劑後之肝臟 磁共振造影圖。 第四(A)圖係顯示未注射 磁共振造影圖。 示未注射F e3 04奈米粒子顯影劑前之腎臟 第四(B)圖係顯示已注射 磁共振造影圖。 第五圖係_示注射 左射FesO4奈米粒子顯影劑後之腎臟 FesO4奈米粒子顯影劑後之大鼠存活 13
Claims (1)
- 拾、、辛請專利範圍: —種水溶性及分散性之Fe3〇4奈米粒子之製造方法,包含下列 步驟: (a) 將含有Fe2+及Fe3+之溶液以1:2〜1:4濃度比例混合; (b) 加入適量之有機酸作為附著劑,該有機酸係選自下列群 組:醋酸、半胱胺酸(cysteine)、丙胺酸(Alanine)、甘 胺酸(glycine)及油酸; (c) 將溶液pH值控制至10以上使沉澱物產生; (d) 收集並清洗該沉澱物; (e) 再加入過量之有機酸作為附著劑,該有機酸係選自下列 群組:醋酸、半胱胺酸(cysteine)、丙胺酸(Alanine)、 甘胺酸(glycine)及油酸; (f) 加入適當有機溶劑及水以去除前述過量之有機酸;及 (g) 收集純化後之Fe3〇4奈米粒子。 2·如申請專利範圍第1項所述之水溶性及分散性之Fe3〇4奈米粒 子之製造方法,其中前述Fe2+及Fe3+溶液之濃度混合比例係為 1:2。 Q •如申請專利範圍第1項所述之水溶性及分散性之Fe3〇4奈米粒 子之製造方法,其中前述有機酸係為甘胺酸。 4·如申請專利範圍第1項所述之水溶性及分散性之Fe3〇4奈米粒 子之製造方法’其中前述步驟(b)及(e)係可使用相同或不相同 有機酸。 5·如申請專利範圍第4項所述之水溶性及分散性之Fe3〇4奈米粒 6子之製造方法,其中前述步驟(b)及(e)係使用相同之有機酸。 •如申請專利範圍第5項所述之水溶性及分散性之Fe3〇4奈米粒 7子之製造方法,其中前述有機酸係為甘胺酸。 •如申睛專利範圍第1項所述之水溶性及分散性之Fe3〇4奈米粒 子之製造方法,農中鈐、+、止 8.如申請專利範圍第Μ二驟⑹,沉澱物係為F· 子之製造方法,其中前之水洛性及分散性之Μ奈米粒 組··丙酮、甲醇、乙醇及^驟⑴之有機溶劑係可選自下列群 及正己烷。 • 申凊專利範圍第§頊戶斤;十、 子之製造方法,Ιφι、 水溶性及分散性之Fe^奈米粒 ίο u 其雨述有機溶劑係為丙嗣。 粒子之ΞίΠ:項所述之水溶性及分散性之㈣4奈米 裟以方法,其係於20〜40。(:下進行。 I =申=專利範圍第10項所述之水溶性及分散性之㈣ 杻子之製造方法,其係於25tT進行。 12.如中請專利範圍第1項所述之水溶性及分散性之⑽夺米 粒子之製造方法,其中前述Fe3〇4奈米粒子之大小為6 2四+ 2· 2 nm。 ~ •種磁共振造影顯影劑,主要係包含由申請專利範圍第1 一 12 項中任一項所述之方法所製成之水溶性及分散性之Fe3〇4奈米 粒子及水。 14.如申請專利範圍第13項所述之磁共振造影顯影劑,其中前述 之Fe3〇4奈米粒子之大小為6· 2nm ± 2. 2 nm。 15
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW092121052A TW588018B (en) | 2003-07-31 | 2003-07-31 | Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof |
US10/882,210 US20050271593A1 (en) | 2003-07-31 | 2004-07-02 | Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof |
DE102004035803A DE102004035803B4 (de) | 2003-07-31 | 2004-07-23 | Verfahren zur Herstellung von in Wasser dispergierten Eisenoxid-Nanoteilchen und deren Anwendung |
US12/081,715 US20080299047A1 (en) | 2003-07-31 | 2008-04-21 | Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW092121052A TW588018B (en) | 2003-07-31 | 2003-07-31 | Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
TW588018B true TW588018B (en) | 2004-05-21 |
Family
ID=34059543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092121052A TW588018B (en) | 2003-07-31 | 2003-07-31 | Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof |
Country Status (3)
Country | Link |
---|---|
US (1) | US20050271593A1 (zh) |
DE (1) | DE102004035803B4 (zh) |
TW (1) | TW588018B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005030301B4 (de) * | 2005-06-27 | 2007-06-06 | Institut für Physikalische Hochtechnologie e.V. | Verfahren zur Herstellung von nanokristallinen magnetischen Eisenoxidpulvern |
CZ301067B6 (cs) * | 2006-02-24 | 2009-10-29 | Ústav makromolekulární chemie AV CR | Superparamagnetické nanocástice na bázi oxidu železa s modifikovaným povrchem, zpusob jejich prípravy a použití |
US7892520B2 (en) * | 2006-07-31 | 2011-02-22 | The Hong Kong University Of Science And Technology | Solid-state synthesis of iron oxide nanoparticles |
KR100962181B1 (ko) | 2008-04-28 | 2010-06-10 | 한국화학연구원 | 피셔-트롭쉬 합성용 철계 촉매 및 이의 제조방법 |
WO2010002922A2 (en) * | 2008-06-30 | 2010-01-07 | Life Technologies Corporation | Methods for isolating and purifying nanoparticles from a complex medium |
US8846644B2 (en) | 2009-09-25 | 2014-09-30 | National Cheng-Kung University | Phosphate-containing nanoparticle delivery vehicle |
US8828975B2 (en) | 2009-09-25 | 2014-09-09 | National Cheng-Kung University | Phosphate-containing nanoparticle delivery vehicle |
TW201110984A (en) * | 2009-09-25 | 2011-04-01 | Univ Nat Cheng Kung | Nanoparticle delivery vehicle |
IT1397612B1 (it) * | 2009-12-15 | 2013-01-18 | Colorobbia Italia Spa | Magnetite in forma nanoparticellare |
CN110194490A (zh) * | 2019-06-14 | 2019-09-03 | 长春工程学院 | 一种制备磁性纳米四氧化三铁的方法和装置 |
CN116004303A (zh) * | 2022-12-02 | 2023-04-25 | 中国科学院兰州化学物理研究所 | 一种水溶性Fe3O4@PEG核壳结构纳米复合添加剂的制备方法及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL98744A0 (en) * | 1990-07-06 | 1992-07-15 | Gen Hospital Corp | Method of studying biological tissue using monocrystalline particles |
US5240626A (en) * | 1990-09-21 | 1993-08-31 | Minnesota Mining And Manufacturing Company | Aqueous ferrofluid |
US5648124A (en) * | 1993-07-09 | 1997-07-15 | Seradyn, Inc. | Process for preparing magnetically responsive microparticles |
US20040115345A1 (en) * | 2002-07-23 | 2004-06-17 | Xueying Huang | Nanoparticle fractionation and size determination |
-
2003
- 2003-07-31 TW TW092121052A patent/TW588018B/zh not_active IP Right Cessation
-
2004
- 2004-07-02 US US10/882,210 patent/US20050271593A1/en active Pending
- 2004-07-23 DE DE102004035803A patent/DE102004035803B4/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20050271593A1 (en) | 2005-12-08 |
DE102004035803A1 (de) | 2005-03-03 |
DE102004035803B4 (de) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shen et al. | Iron oxide nanoparticle based contrast agents for magnetic resonance imaging | |
Silva et al. | Gold coated magnetic nanoparticles: from preparation to surface modification for analytical and biomedical applications | |
Fang et al. | Multifunctional magnetic nanoparticles for medical imaging applications | |
Ferreira et al. | The role of magnetic nanoparticles in cancer nanotheranostics | |
Bae et al. | Bioinspired synthesis and characterization of gadolinium-labeled magnetite nanoparticles for dual contrast T 1-and T 2-weighted magnetic resonance imaging | |
Rammohan et al. | Nanodiamond–gadolinium (III) aggregates for tracking cancer growth in vivo at high field | |
Felton et al. | Magnetic nanoparticles as contrast agents in biomedical imaging: recent advances in iron-and manganese-based magnetic nanoparticles | |
Rowe et al. | Tuning the magnetic resonance imaging properties of positive contrast agent nanoparticles by surface modification with RAFT polymers | |
Li et al. | Hyaluronic acid-modified hydrothermally synthesized iron oxide nanoparticles for targeted tumor MR imaging | |
Miguel-Sancho et al. | Development of stable, water-dispersible, and biofunctionalizable superparamagnetic iron oxide nanoparticles | |
US9468607B2 (en) | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging | |
EP2658896B1 (en) | Biocompatible agent for dispersing nanoparticles into an aqueous medium using mussel adhesive protein-mimetic polymer | |
Polito et al. | Resolving the structure of ligands bound to the surface of superparamagnetic iron oxide nanoparticles by high-resolution magic-angle spinning NMR spectroscopy | |
Hu et al. | High-performance nanostructured MR contrast probes | |
Mondini et al. | Zwitterion-coated iron oxide nanoparticles: surface chemistry and intracellular uptake by hepatocarcinoma (HepG2) cells | |
Hsu et al. | Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications | |
CN103143043B (zh) | 一种Fe3O4/Au复合纳米颗粒的制备方法 | |
TW588018B (en) | Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof | |
KR101592235B1 (ko) | 단백질 케이지의 제조방법 및 소수성 첨가제를 담지한 코어-쉘 구조의 고분자-단백질 입자의 in-situ 제조방법 | |
CN102333547A (zh) | 用于诊断成像的纳米颗粒造影剂 | |
CN104436220B (zh) | 一种壳聚糖磁性纳米微球的制备方法及其用途 | |
Hemalatha et al. | Fabrication and characterization of dual acting oleyl chitosan functionalised iron oxide/gold hybrid nanoparticles for MRI and CT imaging | |
Walter et al. | Validation of a dendron concept to tune colloidal stability, MRI relaxivity and bioelimination of functional nanoparticles | |
Vu-Quang et al. | Carboxylic mannan-coated iron oxide nanoparticles targeted to immune cells for lymph node-specific MRI in vivo | |
Yang et al. | Role of surface charge in cytotoxicity of charged manganese ferrite nanoparticles towards macrophages |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |